E-viri
Recenzirano
Odprti dostop
-
Eskander, Ramez N.; Sill, Michael W.; Beffa, Lindsey; Moore, Richard G.; Hope, Joanie M.; Musa, Fernanda B.; Mannel, Robert; Shahin, Mark S.; Cantuaria, Guilherme H.; Girda, Eugenia; Mathews, Cara; Kavecansky, Juraj; Leath, Charles A.; Gien, Lilian T.; Hinchcliff, Emily M.; Lele, Shashikant B.; Landrum, Lisa M.; Backes, Floor; O’Cearbhaill, Roisin E.; Al Baghdadi, Tareq; Hill, Emily K.; Thaker, Premal H.; John, Veena S.; Welch, Stephen; Fader, Amanda N.; Powell, Matthew A.; Aghajanian, Carol
The New England journal of medicine, 06/2023, Letnik: 388, Številka: 23Journal Article
In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.
